Kimberly Yonkers to Antidepressive Agents, Second-Generation
This is a "connection" page, showing publications Kimberly Yonkers has written about Antidepressive Agents, Second-Generation.
Connection Strength
0.922
-
Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N, Luchansky E, Lin H, Belanger K. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology. 2012 Sep; 23(5):677-85.
Score: 0.406
-
Yonkers KA. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes. Psychopharmacol Bull. 2003; 37 Suppl 1:135-47.
Score: 0.208
-
Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb; 16(1):3-8.
Score: 0.129
-
Garlow SJ, Kinkead B, Thase ME, Judd LL, Rush AJ, Yonkers KA, Kupfer DJ, Frank E, Schettler PJ, Rapaport MH. Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res. 2013 Sep; 47(9):1199-203.
Score: 0.107
-
Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, Vogel GW, Kaplita SB, Fleming JB, Montplaisir J, Erman MK, Albala BJ, McQuade RD. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998 Jul 01; 44(1):3-14.
Score: 0.038
-
Armitage R, Yonkers K, Cole D, Rush AJ. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol. 1997 Jun; 17(3):161-8.
Score: 0.035